Loading
Nanoparticles / Rotavirus Vaccines / Rotavirus Infections · Journal article
Human Vaccines & Immunotherapeutics · June 11, 2026
Raises a question worth testing. It does not answer one.
This review proposes nanomaterial-based vaccine platforms (lipid, polymeric, metallic nanoparticles, VLPs, and pseudovirus nanoparticles) as an advanced approach to overcome the reduced efficacy of live-attenuated oral rotavirus vaccines in low- and middle-income countries. The authors hypothesize that these non-replicating platforms could bypass gut-related barriers such as malnutrition, intestinal dysbiosis, and environmental enteric dysfunction that currently limit vaccine performance.
Journal article. Children under 5 years old globally, particularly in low- and middle-income countries.
Live-attenuated rotavirus vaccine effectiveness is 80–90% in high-income countries compared to 40–70% in low- and middle-income countries Nanomaterial platforms are proposed to overcome problems related to vaccine uptake and replication in an impaired gut by using highly immunogenic parenteral vaccines Rotavirus VLPs are composed of structural proteins VP2, VP6, and VP7 that self-assemble into noninfectious particles mimicking the native virus
No safety, immunogenicity, or efficacy outcomes from nanomaterial-based rotavirus vaccine candidates are provided
Clinicians should recognize that current live-attenuated oral rotavirus vaccines show substantially reduced efficacy in resource-limited settings due to gut microbiome dysbiosis and environmental enteric dysfunction. Nanomaterial-based platforms represent a theoretical strategy under development, but no clinical efficacy or safety data are presented in this review.
This is a narrative review proposing nanomaterial-based vaccines as a solution to rotavirus vaccine efficacy gaps in LMICs, without presenting original experimental data or clinical trial results.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize that current live-attenuated oral rotavirus vaccines show substantially reduced efficacy in resource-limited settings due to gut microbiome dysbiosis and environmental enteric dysfunction. Nanomaterial-based platforms represent a theoretical strategy under development, but no clinical efficacy or safety data are presented in this review.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Rotavirus remains a primary cause of severe dehydrating diarrhea in children globally, particularly in low- and middle-income countries (LMICs). While live-attenuated oral vaccines have significantly reduced the disease burden, their efficacy is particularly reduced in conditions characterized by malnutrition, intestinal dysbiosis, and environmental enteric dysfunction (EED). This review examines a diverse range of technologies, including lipid, polymeric, and metallic nanoparticles, as well as virus-like particles (VLPs) and pseudovirus nanoparticles (PVNPs), and analyzes their potential for enhanced antigen stability, targeted delivery, and potent immunogenicity. Unlike conventional formulations, these next-generation platforms can be designed as highly immunogenic injectable vaccines to cross the hostile intestinal environment or as protective oral carriers that protect antigens from degradation. Thus, the strategic integration of nanotechnology into rotavirus vaccine design could offer a transformative path to achieving sustained protection and overcoming the biological barriers that currently limit the success of live-attenuated vaccines.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.